Back to search results

Study of Pirtobrutinib for Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma

This study is for people who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), or non-Hodgkin lymphoma, and have already received treatment. It is testing a drug called pirtobrutinib, which is given by mouth. This study is designed for people who are already participating in a previous study (LOXO-BTK-18001) and will allow them to continue receiving pirtobrutinib or continue their follow-up visits. The main goal is to see how many participants experience serious side effects (Grade 3 or higher) from pirtobrutinib. This study aims to enroll 279 participants to evaluate the long-term safety and effectiveness of pirtobrutinib.

Study design
This is an interventional study for participants already in a previous study. It aims to enroll 279 participants.
What's involved
Participants will continue to receive pirtobrutinib or continue their follow-up visits.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for side effects from the first dose through 30 days (+ 7-day window) after the last dose or starting new anti-cancer therapy, whichever is earlier.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06876662

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Recruiting
PHASE4Ages 18+InterventionalTreatment
Eli Lilly and Company
~279 participants
Updated 2026-03-02 on ClinicalTrials.gov
What's tested:Pirtobrutinib

At a glance

Recruiting sites
25 of 36 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of Participants with a Grade ≥3 treatment-emergent adverse events (TEAEs)
Measured over Time from the Date of the First Dose of Study Intervention (Study Day 1) through 30 Days (+ 7-day window) After the Date of the Last Dose of Study Intervention or The First Date Starting a New Anticancer Therapy, whichever is Earlier

Conditions

Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma

Explore related trials

Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma

Where it's being run

36 sites across 21 states
Japan6
New York4
Australia3
United Kingdom3
Florida2
Italy2
Poland2
Georgia1

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
[email protected]
1-317-615-4559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Are currently enrolled and active in the originator study, LOXO-BTK-18001. A participant is considered active in the study if they are:
receiving study intervention
in the short-term follow-up period, or
in the long-term follow-up period

Exclusion

Were a participant in the Phase 1b cohort of Study LOXO-BTK-18001

What this trial measures

  • Percentage of Participants with a Grade ≥3 treatment-emergent adverse events (TEAEs)Time from the Date of the First Dose of Study Intervention (Study Day 1) through 30 Days (+ 7-day window) After the Date of the Last Dose of Study Intervention or The First Date Starting a New Anticancer Therapy, whichever is Earlier